Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;53(10):1813-1818.
doi: 10.1111/imj.15961. Epub 2022 Oct 31.

Metastatic primary breast neuroendocrine neoplasms: a case series

Kathleen Batty  1 , Amelia M Taylor  1 , Elizabeth J Bernard  2 , Connie I Diakos  1   3 , Stephen J Clarke  1   3 , Alexander Guminski  1 , Sally Baron-Hay  1 , Frances Boyle  4   5 , Nick Pavlakis  1   3 , David L Chan  1   3
Affiliations

Metastatic primary breast neuroendocrine neoplasms: a case series

Kathleen Batty et al. Intern Med J. 2023 Oct.

Abstract

Background: Breast neuroendocrine neoplasms represent a rare subtype of breast cancer which have not been well studied or characterised, particularly in the metastatic setting.

Aim: To present clinicopathological characteristics, treatment and outcomes of a series of patients with metastatic neuroendocrine carcinoma of the breast and review the current literature.

Methods: We performed a retrospective review to identify and describe patients with metastatic neuroendocrine carcinoma of the breast at our centre between 2011 and 2021. Medical records, pathology and imaging results were examined to evaluate the clinical and histopathological features as well as the treatment pathways and prognosis of these patients.

Results: We present a series of seven female patients with metastatic neuroendocrine carcinoma of the breast, as defined by the World Health Organization classification, over a period of 10 years (2011-2021) from a single centre. Median age at diagnosis was 48 years (range 39-63). Six of seven tissue samples expressed synaptophysin and chromogranin and were also oestrogen and progesterone receptor positive; median Ki-67 index was 50% (range 20-90%). All seven patients had demonstrated avidity on 18 F-FDG PET imaging, and the six who underwent 68 Ga-DOTATATE PET all had significant avidity. Treatment modalities and sequencing varied, but all patients received chemotherapy during their disease course. Six patients received three or more lines of treatment. Median overall survival was 31.8 months (range 3.7-108.6). Median progression-free survival (PFS) with first-line therapy for metastatic disease was 5.8 months (range 1.8-37.8).

Conclusions: This series shows the use of multiple modalities in treating this disease, with different sequencing in different patients. Despite multiple modalities used in the first-line setting, first-line PFS remains short. Larger series and further molecular characterisation are required to aid clinicians in managing this condition and to guide optimal treatment sequencing to improve outcomes in this rare patient group.

Keywords: breast carcinoma; breast neoplasms; cancer of the breast; malignant neoplasm; neuroendocrine tumour.

PubMed Disclaimer

References

    1. Tsang JY, Tse GM. Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification. Mod Pathol 2021; 34: 1062-73.
    1. Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology 2020; 77: 181-5.
    1. Bussolati G, Badve S. Carcinomas with neuroendocrine features. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH and van de Vijver MJ, eds World Health Organization Classification of Tumours of the Breast, 4th edn. Lyon: IARC Press; 2012; 62-3.
    1. Lavigne M, Menet E, Tille JC, Lae M, Fuhrmann L, Bonneau C et al. Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Mod Pathol 2018; 31: 68-82.
    1. Vranic S, Palazzo J, Sanati S, Florento E, Contreras E, Xiu J et al. Potential novel therapy targets in neuroendocrine carcinomas of the breast. Clin Breast Cancer 2019; 19: 131-6.

Substances